Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01080053
Other study ID # EMR200077-511
Secondary ID
Status Completed
Phase N/A
First received March 2, 2010
Last updated October 13, 2013
Start date November 2008
Est. completion date May 2013

Study information

Verified date October 2013
Source Merck KGaA
Contact n/a
Is FDA regulated No
Health authority Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Study type Observational

Clinical Trial Summary

This is an observational, prospective, non-interventional, non-controlled study planned to be conducted in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS).

The purpose of this observational study is to determine the correlation between the degree of disability and sexual dysfunction; and between the sexual dysfunction and the quality of life (QoL) of subjects with Relapsing Remitting Multiple Sclerosis (RRMS) in Argentina.


Description:

Multiple sclerosis, like most of the chronic diseases, can affect the sexuality of those who suffer from it. This situation has an evident and marked impact on the QoL of the subjects and his/her partner, and causes conflict in the relationship, with high levels of mutual dissatisfaction.

The impact that the duration of the disease or the degree of disability have on the level of sexual dysfunction is not clear. However, the possible organic and state of mind causes of the sexual dysfunction makes us think that the degree of disability is a crucial factor in the genesis and duration of the symptoms in the sexual area. The frequency with which the sexual dysfunction is detected or referred in these subjects is variable.

The sexual dysfunction in subjects with MS is typically characterized by a decreased libido, erectile dysfunction and ejaculation disorders in men, and decreased lubrication and anorgasmia in women. The most commonly detected problems are the erectile dysfunction and/or lack of sexual interest in men and lack of interest, decreased libido and orgasmic disorder in women.

This observational study aims to assess a population of subjects with MS that show symptoms of sexual dysfunction, in order to determine the relationship, if any, between the severity of the general disability and the incidence of sexual dysfunction. At the same time, this epidemiologic study aims to measure the impact the sexual dysfunction generates in the quality of life of subjects with MS.

The data to be obtained could contribute to a better understanding of the relationship between the studied variables and, eventually, to alert the treating doctors about the incidence of these morbid associations.

The total duration of the study is 24 months. The recruiting period will be 12 months. Once the recruiting time is over, the collection of data will continue during the full 24 months period that was planned.


Recruitment information / eligibility

Status Completed
Enrollment 306
Est. completion date May 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender Both
Age group 22 Years and older
Eligibility Inclusion Criteria:

- Men and women > 21 years of age

- Subjects with established diagnosis of RRMS according to the revised McDonald criteria - 2005

- Subjects with a diagnosis of RRMS for more than one year

- The subject who have signed the Informed Consent

Exclusion Criteria:

- Subjects with no sexual experience

- Subjects with other diseases associated to MS

- Subjects with psychiatric diseases that could cause sexual dysfunction

- Subjects with one relapse during the previous month

- Use of antidepressants and/or corticosteroids during the previous month

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Argentina Dr. Norma Deri Buenos Aires

Sponsors (2)

Lead Sponsor Collaborator
Merck KGaA Merck Quimica Argentina S.A.I.C

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary The correlation between the degree of disability and sexual dysfunction, and between the sexual dysfunction and the QoL of subjects Mini-Mental State Examination (MMSE) Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) Hamilton Rating Scale for Depression (HRSD) Initial visit (Day 0) and each follow up visit upto the observation period of 24 months No
See also
  Status Clinical Trial Phase
Completed NCT01080027 - Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) N/A
Completed NCT02247310 - BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon N/A
Completed NCT00859482 - Differential Immune Effects of Natalizumab N/A
Completed NCT02638038 - This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years Phase 2
Completed NCT01080040 - To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients N/A